- Home
- APA vs GKOS Comparison
APA vs GKOS Comparison
Compare APA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APA
- GKOS
- Stock Information
- Founded
- APA 1954
- GKOS 1998
- Country
- APA United States
- GKOS United States
- Employees
- APA N/A
- GKOS N/A
- Industry
- APA Oil & Gas Production
- GKOS Medical/Dental Instruments
- Sector
- APA Energy
- GKOS Health Care
- Exchange
- APA Nasdaq
- GKOS Nasdaq
- Market Cap
- APA 8.7B
- GKOS 8.4B
- IPO Year
- APA N/A
- GKOS 2015
- Fundamental
- Price
- APA $22.79
- GKOS $125.83
- Analyst Decision
- APA Hold
- GKOS Strong Buy
- Analyst Count
- APA 19
- GKOS 13
- Target Price
- APA $30.17
- GKOS $161.00
- AVG Volume (30 Days)
- APA 6.3M
- GKOS 671.3K
- Earning Date
- APA 02-26-2025
- GKOS 02-20-2025
- Dividend Yield
- APA 4.39%
- GKOS N/A
- EPS Growth
- APA 34.29
- GKOS N/A
- EPS
- APA 6.58
- GKOS N/A
- Revenue
- APA $8,955,000,000.00
- GKOS $383,481,000.00
- Revenue This Year
- APA $11.10
- GKOS $22.69
- Revenue Next Year
- APA N/A
- GKOS $26.76
- P/E Ratio
- APA $3.46
- GKOS N/A
- Revenue Growth
- APA 6.11
- GKOS 21.85
- 52 Week Low
- APA $20.32
- GKOS $83.90
- 52 Week High
- APA $36.05
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- APA 48.41
- GKOS 29.90
- Support Level
- APA $22.10
- GKOS $142.51
- Resistance Level
- APA $23.98
- GKOS $161.78
- Average True Range (ATR)
- APA 0.79
- GKOS 5.74
- MACD
- APA 0.09
- GKOS -1.65
- Stochastic Oscillator
- APA 57.95
- GKOS 2.39
About APA APA Corporation
Based in Houston, APA is an independent exploration and production company. It operates primarily in the US, Egypt, the North Sea, and Suriname. At year-end 2023, proved reserves totaled 807 million barrels of oil equivalent, with net reported production of 405 thousand boe/day that year (64% of which was oil and natural gas liquids, with the remainder natural gas).
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.